Skip to main
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros is making strides in its YARTEMLEA launch, with positive feedback from physicians, significant institutional access secured, and promising pediatric uptake. Its pipeline also provides additional potential, with OMS1029 and OMS527 both advancing to Phase 2 and promising results from its OncotoX-AML and T-CAT platform programs. Coupled with its strong financial profile and positive outlook for reimbursement and market uptake, Omeros appears to have a solid path to positive cash flow and continued growth. However, there are still risks to consider, such as clinical, regulatory, financial, commercial, and legal and intellectual property factors, which could impact its overall performance.

Bears say

Omeros is a high-risk investment, with regulatory, clinical development, commercialization, intellectual property, and pipeline development risks. While Omeros's pipeline shows potential with a regulatory decision on YARTEMLEA expected in mid-2026 and upcoming earnings calls, its financials and management's commentary on commercial infrastructure will be crucial factors to monitor as the company moves forward.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of May 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.